TSL Thinksmart Limited

RNS Number:2285N
Tissue Science Laboratories PLC
07 June 2005


7 June 2005
                        
                         Tissue Science Laboratories plc
                            ('TSL' or 'the Company')

                      Grant of Share Options to Directors

Tissue Science Laboratories plc (LSE: TSL), the medical devices company
specialising in human tissue replacement and repair products derived from
porcine dermis, announces today that share options have been granted to three
Directors:

Martin Hunt, Chief Executive        100,000

David Jennings, Finance Director     80,000

Steve Bloor, Technical Director      85,000

Date of grant: 7 June, 2005

Period during which exercisable: minimum 5 year vesting period

Description of shares involved: 265,000 of ordinary shares

Exercise price: #1.70
                                     -Ends-

For further information, please contact:

TSL plc                                              Tel: 01252 369603
Martin Hunt, Chief Executive

Hogarth Partnership Limited                          Tel: 020 7357 9477
Melanie Toyne-Sewell / Kate Catchpole

Notes to Editors

Background on TSL

Founded in 1995, with headquarters in Aldershot, Hampshire, TSL is a medical
technology company specialising in tissue repair and replacement with a
proprietary sheet product, derived from porcine dermis, called Permacol(R). TSL
has launched successfully different formulations of the product and built a
development pipeline that addresses the large and fast growing surgical implant
market. The Company floated in November 2001 and is listed on the Alternative
Investment Market (LSE: TSL). TSL has a family of products based on the same
core technology. Each product has been adapted, with unique properties, to make
it suitable for use in different applications, including urology/gynaecology,
complex and recurrent hernia repair, shoulder rotator cuff repair and head and
face repair and reconstruction. The Company has signed distribution agreements
with CR Bard Inc (urology/gynaecology - worldwide), Zimmer Inc (orthopaedic -
worldwide) and Porex Surgical Inc (head & ace-US and Canada). Further variations
of the sheet and injectable forms of Permacol(R) are being developed.

Background on Permacol(R)

Permacol(R) was developed at Dundee University over a 20 year time period and
has been patented worldwide. The key to the Permacol(R) concept lies in it
collagen Technology which uses non-reconstituted porcine dermal collagen, very
similar in structure to human tissue. Non-collagenous material, except elastin,
is removed by the TSL manufacturing process. The remaining collagen, which
retains its original 3 D structural architecture, is stabilised by a patented
cross-linking process. The result is a non-reconstituted, non-allergenic,
collagen implant which is resistant to biodegradation attack, is recognised and
accepted by the body, and is able to provide a long-term support for the
in-growth of new tissue and its associated blood supply.


                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
RDSBDLFBEQBFBBQ

Grafico Azioni Thinksmart (LSE:TSL)
Storico
Da Giu 2024 a Lug 2024

Grafico Azioni Thinksmart (LSE:TSL)
Storico
Da Lug 2023 a Lug 2024